Veradermics, Inc MANE
Veradermics, Inc (NYSE: MANE) is a dermatology drug developer. Its lead program, VDPHL01, is in Phase 3 for Pattern hair loss (male and female). Its next catalyst on record is VDPHL01: Topline data from Part B of Study '302' (male pattern hair loss) anticipated in the second half of 2026. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VDPHL01 — Topline data from Part B of Study '302' (male pattern hair loss) anticipated in the second half of 2026. (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VDPHL01 - male Phase 3 (536 pts, fully enrolled) and male Phase 2/3 Study 302 (519 pts; positive topline April 2026) | Pattern hair loss, men | small molecule | Phase 3 |
| VDPHL01 - female Phase 2/3 Study 306 (552 pts target; enrollment complete) | Pattern hair loss, women | small molecule | Phase 3 |
| VDPHL01 - Phase 2 Study 207 (open label, men and women; positive topline July 2026) | Pattern hair loss | small molecule | Phase 2 |
Recent results and decisions
- Oct 19, 2026met Phase 3 Study 304 met all primary and secondary endpoints: non-vellus TAHC +28.6 (QD) and +36.4 (BID) hairs/cm2 vs +6.6 placebo at Month 6, p<0.0001; PRO improved/much improved 55.7%/68.7% vs 15.0%.
Participants achieved an average increase in non-vellus hair count of 28.6 hairs/cm² (p<0.0001) and 36.4 hairs/cm² (p<0.0001) in once-daily and twice-daily VDPHL01 treatment arms, respectively.
Filing - Aug 11, 2026completed enrollment Enrollment completed in Phase 2/3 Study 306 (556 women with female pattern hair loss).
Veradermics has completed enrollment of Study ‘306’, a Phase 2/3 multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of VDPHL01 at two dose regimens (4.5 mg once-daily and twice-daily) over 52 weeks in 556 female participants with mild-to-moderate patt
Filing - Jul 15, 2026positive Open-label Phase 2 Study 207 in women: non-vellus TAHC +22.7 (QD) and +23.3 (BID) hairs/cm2 at Month 6; 88.9%/90.0% reported improved or much improved; no treatment-related SAEs.
Participants achieved an average increase in non-vellus hair count of 22.7 hairs/cm² and 23.3 hairs/ cm² in once daily and twice daily VDPHL01 treatment arms, respectively.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.